News

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...
A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...
An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...
Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...
GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.
This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...
Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...
A new study by researchers at Unity Health, Sunnybrook Health Sciences Center and the University of Toronto has found that ...
Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.
The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...
The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...